A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market
Drug development for HCV antivirals has exploded with rising incidence rates (including in developed countries) and the intense need for curative therapy in the absence of a preventative vaccine.
A treatment revolution is underway as the market moves away from protease inhibitors and interferon regimens and toward highly-effective, easily tolerated interferon-free oral therapies, with Gilead’s sofosbuvir/Sovaldi winning the race to the market and estimating stratospheric numbers in 2014 ($ + billion). Sofosbuvir’s uptake, however, could be slowed by its steep price, which has unleashed a firestorm of criticism from government agencies, patient advocacy groups, and (most importantly) payers. Analysts expect the next-to-market all-orals to compete aggressively on price in an effort to erode Gilead’s share.
With the introduction of potent all-oral regimens (so-called “terminator” therapies), the treatment paradigm is shifting from disease management to eradication. Nevertheless, there are areas ripe for innovation, notably the development of an all-oral pan-genotypic therapy and a or week treatment regimen.
The next 3 potential launches for HCV are ABT-450/ABT-267/ABT-333/RBV, GS-7977/GS-5885 FDC, and daclatasvir/asunaprevir.
While it is unlikely to hit the market before late 2015/early 2016, Merck’s 5172/8142—a single, once-daily tablet—is projected to rival AbbVie’s entry as the 2nd entrant given its dosing advantage and stellar Phase 2 data.
About this report
This research service focuses on antiviral therapeutics for the treatment of the hepatitis C virus (HCV). A global product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HCV. Segmentation by drug class is provided, along with supporting information such as clinical trial timelines and results, key market developments, historical and projected launch timelines, and epidemiology. The information contained in this research was derived from published sources, including disease organizations; public health organizations; company publications including annual reports, SEC filings, and press releases; government public sources; and articles in scientific journals.
Electronic Access - Site License Fulfilled by Publisher
Electronic Access - Global site License Fulfilled By Publisher